These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

537 related articles for article (PubMed ID: 37513928)

  • 1. The Vital Role Played by Deferiprone in the Transition of Thalassaemia from a Fatal to a Chronic Disease and Challenges in Its Repurposing for Use in Non-Iron-Loaded Diseases.
    Kontoghiorghes GJ
    Pharmaceuticals (Basel); 2023 Jul; 16(7):. PubMed ID: 37513928
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transfusional iron overload and chelation therapy with deferoxamine and deferiprone (L1).
    Kontoghiorghes GJ; Pattichi K; Hadjigavriel M; Kolnagou A
    Transfus Sci; 2000 Dec; 23(3):211-23. PubMed ID: 11099897
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Benefits and risks of deferiprone in iron overload in Thalassaemia and other conditions: comparison of epidemiological and therapeutic aspects with deferoxamine.
    Kontoghiorghes GJ; Neocleous K; Kolnagou A
    Drug Saf; 2003; 26(8):553-84. PubMed ID: 12825969
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The design and development of deferiprone (L1) and other iron chelators for clinical use: targeting methods and application prospects.
    Kontoghiorghes GJ; Pattichis K; Neocleous K; Kolnagou A
    Curr Med Chem; 2004 Aug; 11(16):2161-83. PubMed ID: 15279556
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The History of Deferiprone (L1) and the Paradigm of the Complete Treatment of Iron Overload in Thalassaemia.
    Kontoghiorghes GJ; Kleanthous M; Kontoghiorghe CN
    Mediterr J Hematol Infect Dis; 2020; 12(1):e2020011. PubMed ID: 31934321
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Desferrioxamine mesylate for managing transfusional iron overload in people with transfusion-dependent thalassaemia.
    Fisher SA; Brunskill SJ; Doree C; Gooding S; Chowdhury O; Roberts DJ
    Cochrane Database Syst Rev; 2013 Aug; (8):CD004450. PubMed ID: 23963793
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Advances in iron overload therapies. prospects for effective use of deferiprone (L1), deferoxamine, the new experimental chelators ICL670, GT56-252, L1NA11 and their combinations.
    Kontoghiorghes GJ; Eracleous E; Economides C; Kolnagou A
    Curr Med Chem; 2005; 12(23):2663-81. PubMed ID: 16305464
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia.
    Fortin PM; Fisher SA; Madgwick KV; Trivella M; Hopewell S; Doree C; Estcourt LJ
    Cochrane Database Syst Rev; 2018 May; 5(5):CD012349. PubMed ID: 29737522
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral deferiprone for iron chelation in people with thalassaemia.
    Fisher SA; Brunskill SJ; Doree C; Chowdhury O; Gooding S; Roberts DJ
    Cochrane Database Syst Rev; 2013 Aug; (8):CD004839. PubMed ID: 23966105
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with non-transfusion-dependent thalassemia syndromes.
    Kontoghiorghe CN; Kontoghiorghes GJ
    Drug Des Devel Ther; 2016; 10():465-81. PubMed ID: 26893541
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New developments and controversies in iron metabolism and iron chelation therapy.
    Kontoghiorghe CN; Kontoghiorghes GJ
    World J Methodol; 2016 Mar; 6(1):1-19. PubMed ID: 27019793
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effective new treatments of iron overload in thalassaemia using the ICOC combination therapy protocol of deferiprone (L1) and deferoxamine and of new chelating drugs.
    Kontoghiorghes GJ; Kolnagou A
    Haematologica; 2006 Jun; 91(6 Suppl):ELT04. PubMed ID: 16785141
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chelation protocols for the elimination and prevention of iron overload in thalassaemia.
    Kolnagou A; Kontoghiorghes GJ
    Front Biosci (Landmark Ed); 2018 Jan; 23(6):1082-1098. PubMed ID: 28930590
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Deferiprone: a review of its clinical potential in iron overload in beta-thalassaemia major and other transfusion-dependent diseases.
    Barman Balfour JA; Foster RH
    Drugs; 1999 Sep; 58(3):553-78. PubMed ID: 10493280
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A risk-benefit assessment of iron-chelation therapy.
    Porter JB
    Drug Saf; 1997 Dec; 17(6):407-21. PubMed ID: 9429839
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prospects for the introduction of targeted antioxidant drugs for the prevention and treatment of diseases related to free radical pathology.
    Kontoghiorghes GJ; Kontoghiorghe CN
    Expert Opin Investig Drugs; 2019 Jul; 28(7):593-603. PubMed ID: 31185180
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New concepts of iron and aluminium chelation therapy with oral L1 (deferiprone) and other chelators. A review.
    Kontoghiorghes GJ
    Analyst; 1995 Mar; 120(3):845-51. PubMed ID: 7741239
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical use, therapeutic aspects and future potential of deferiprone in thalassemia and other conditions of iron and other metal toxicity.
    Kontoghiorghes GJ
    Drugs Today (Barc); 2001 Jan; 37(1):23-35. PubMed ID: 12783095
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of iron salts, haemosiderins, and chelating agents on the lymphocytes of a thalassaemia patient without chelation therapy as measured in the comet assay.
    Anderson D; Yardley-Jones A; Vives-Bauza C; Chua-Anusorn W; Cole C; Webb J
    Teratog Carcinog Mutagen; 2000; 20(5):251-64. PubMed ID: 10992272
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Iron-balance and dose-response studies of the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1) in iron-loaded patients with sickle cell disease.
    Collins AF; Fassos FF; Stobie S; Lewis N; Shaw D; Fry M; Templeton DM; McClelland RA; Koren G; Olivieri NF
    Blood; 1994 Apr; 83(8):2329-33. PubMed ID: 8161801
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.